![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pre-exposure prophylaxis (PrEP) prescriptions
among individuals at high risk for HIV in the United States, 2012-2018
|
|
|
IDWeek 2021; September 29-October 3, 2021.
Mo Zhou1; Yan Song1; Emily Gao1; Yohance Whiteside2; Emma Billmyer1; James Signorovitch1
1Analysis Group, Inc., Boston, MA, USA; 2Merck & Co., Inc., Kenilworth, NJ, USA
![1001211](../images/100121/100121-4/1001211.gif)
![1001212](../images/100121/100121-4/1001212.gif)
![1001213](../images/100121/100121-4/1001213.gif)
![1001214](../images/100121/100121-4/1001214.gif)
![1001215](../images/100121/100121-4/1001215.gif)
![1001216](../images/100121/100121-4/1001216.gif)
![1001217](../images/100121/100121-4/1001217.gif)
![1001218](../images/100121/100121-4/1001218.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|